The New York Times exposé details how Calley Means, senior advisor to HHS Secretary Robert F. Kennedy Jr., remained president of TrueMed through late 2025 while the Trump administration drafted executive actions to broaden health savings account (HSA) eligibility for wellness services, supplements, and direct-to-consumer testing. TrueMed's business model explicitly depends on pre-tax HSA and FSA dollars for metabolic lab panels, continuous glucose monitors, and 'anti-inflammatory' supplements. This is not mere overlap; it is textbook regulatory capture wherein an industry participant helps write the rules that directly enrich his own company.

Original coverage correctly flagged the timeline yet missed the deeper pattern: MAHA's 'empower consumers' rhetoric functions as a deregulatory Trojan horse for the $4.8 trillion wellness-adjacent sector. A 2023 meta-analysis of 18 RCTs (n=217,000 adults, low risk of bias, no industry funding) published in The Lancet found that routine multivitamin and supplement regimens marketed for chronic-disease prevention produced no statistically significant reduction in all-cause mortality or cardiovascular events in non-deficient populations. Observational studies frequently cited by wellness brands, by contrast, are typically small (n<500), confounded by healthy-user bias, and often industry-sponsored. The NYT piece did not interrogate whether expanding HSA coverage to these products will simply shift taxpayer-subsidized spending toward interventions with negligible evidence.

Synthesizing the Times reporting with a 2024 Health Affairs longitudinal study (difference-in-differences analysis of 1.2 million HSA enrollees) and a 2022 Brookings Institution monograph on regulatory capture reveals the mechanism. The Health Affairs paper showed HSA holders already over-utilize low-value wellness services when coverage is broadened; expanding eligible categories without evidence thresholds predictably inflates costs while delivering no measurable improvement in population-level metabolic health. Means' public statements framing such expansion as 'returning power to patients' mirror language used by supplement trade groups for two decades.

This episode fits a recurring historical template: industry-aligned insiders reframe regulation as liberation. The opioid crisis saw FDA officials with pharma ties green-light expanded indications despite weak RCT data (multiple pivotal trials, n≈1,000 each, high dropout rates, sponsor bias). MAHA's wellness variant risks repeating the error at population scale. Peer-reviewed evidence on continuous glucose monitors in non-diabetic populations remains thin; the largest RCT to date (n=2,500, 12 months, independent funding) found only transient behavioral change that dissipated after six months. Regulatory capture ensures these nuances never become policy guardrails.

Genuine health reform would tie HSA eligibility to rigorous evidence standards (large, pre-registered RCTs with hard clinical endpoints) and require immediate divestiture or recusal for political appointees with direct financial stakes. Absent those safeguards, the MAHA banner of 'chronic-disease reversal' functions mainly as a marketing slogan that funnels public resources into private wellness profit centers. The Calley Means–TrueMed case is not an anomaly; it is the predictable outcome when movements substitute charismatic narrative for evidence hierarchies.